Wiley and OpenEvidence Partner to Deliver Trusted Research to Physicians at the Point of Care

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Positive)

Key Terms

peer-reviewed medical

Peer-reviewed means a study, report or paper has been examined and approved by independent experts in the same field before publication, like having multiple qualified inspectors check a building plan. For investors, peer review signals that methods and conclusions have passed scrutiny beyond the author’s claims, making scientific, clinical or technical findings more reliable and reducing the chance that decisions or valuation are based on unchecked or flawed evidence.

systematic reviews medical

A systematic review is a careful, structured summary of all available studies on a specific question—often about a medical treatment or technology—using predefined rules to find, evaluate and combine results so conclusions are less likely to be skewed by one-off studies. For investors, it acts like a thorough audit of the evidence: it reduces uncertainty about a drug’s or product’s real effects and helps assess regulatory, clinical and commercial risks before making funding or valuation decisions.

clinical guidelines medical

Clinical guidelines are systematically developed recommendations from medical experts that outline the best ways to diagnose, treat, and manage specific health conditions; think of them as a trusted recipe or roadmap for doctors to follow. Investors care because these guidelines shape which tests, drugs, and devices become standard practice, driving demand, pricing, and insurance coverage — changes that can significantly affect a healthcare company's revenue and market value.

evidence syntheses medical

Evidence syntheses are structured reviews that gather, compare and summarize results from multiple studies to show the overall picture of what the research says about a treatment, product or risk. For investors, they matter because these summaries reduce the noise of individual studies—like reading a condensed report card instead of dozens of test answers—helping assess the strength of scientific or clinical claims that can affect a company’s regulatory prospects, market potential and risk profile.

clinical practice medical

The routine delivery of medical care by doctors, nurses and other healthcare providers in hospitals, clinics and offices — essentially how a treatment or procedure is used in everyday medicine rather than in controlled research. Investors care because widespread clinical practice determines real-world demand, reimbursement, and long-term sales: it's the difference between a product proving it can work in trials and it becoming a commonly used tool on the medical ‘road.’

point of care medical

Point of care is the place and moment where a patient receives medical attention or testing — for example, a doctor's office, clinic, bedside, or urgent care — rather than a distant laboratory. For investors, point‑of‑care products matter because they speed diagnosis and treatment, lower costs, and can increase demand for portable tests and devices in many healthcare settings, much like having a home thermometer instead of sending samples away.

biomedical research medical

Biomedical research studies living systems—cells, tissues, animals and people—to understand how diseases start, how the body responds, and how new tests, medicines, devices or procedures might prevent, diagnose or treat illness. For investors, it’s the engine that can create patentable products, regulatory milestones and new revenue streams; think of it as planting seeds that may take years to grow but can dramatically change a company’s prospects if they succeed.

clinical decisions medical

Clinical decisions are the judgments clinicians and research teams make about patient care and how medical tests or treatments are used, such as choosing whom to treat, which measurements to track, or when to stop a trial. For investors, these choices shape a drug or device’s development path, trial outcomes and regulatory chances—like a navigator picking a course that affects how quickly and safely a product can reach the market.

03/03/2026 - 08:00 AM

A new content agreement deepens the medical literature physicians can retrieve, synthesize, and verify through AI-assisted clinical questions

HOBOKEN, N.J.--(BUSINESS WIRE)-- Wiley (NYSE: WLY), a global leader in authoritative content and research intelligence for the advancement of clinical practice, scientific discovery and learning, and OpenEvidence, the most widely used medical AI platform in the world, today announced a strategic partnership to bring Wiley's trusted scientific and medical content into OpenEvidence. Through the partnership, physicians using OpenEvidence at the point of care can rely on content from hundreds of Wiley’s peer-reviewed journals and resources across key medical specialties to support their clinical decisions.

Medical knowledge doubles every 73 days. Historically, published research has taken an average of 17 years to reach clinical practice. Helping doctors make point-of-care decisions grounded in the best and latest science requires more than capable AI; it needs the right underlying content. OpenEvidence was built on a principle its founders call “gold in, gold out”: specialized models trained on peer-reviewed literature, not the open internet, with every answer grounded in sources a physician can drill into and verify. By joining OpenEvidence’s existing network of content partners, Wiley extends that foundation.

“The hard problem in medicine right now isn’t just generating new knowledge. We are living through a golden age of biomedical research. The hard problem is also that it takes 17 years for a fraction of that research to reach the bedside,” said Daniel Nadler, founder of OpenEvidence. “Wiley is an ideal partner in solving this problem for physicians. The depth and breadth of Wiley’s content reinforce the advantages of OpenEvidence for physicians, and that compounds over time.”

Wiley will license a comprehensive portfolio of scientific and medical content to OpenEvidence, including the Cochrane Database of Systematic Reviews—the home of gold standard evidence syntheses, widely used to inform clinical guidelines worldwide—and Cochrane Clinical Answers—a curated collection of actionable clinical insights drawn from Cochrane reviews.

“Cochrane systematic reviews are relied upon by evidence users worldwide, from patients and healthcare professionals to guideline-setters and policymakers,” said Karla Soares-Weiser, CEO of Cochrane. “AI is rapidly changing the ways that people use and access evidence, and we hope that this partnership helps to ensure that outputs from AI-powered tools are based on the best possible evidence.”

Additionally, the portfolio will comprise over 400 Wiley journals and books, including authoritative medical references such as Holland-Frei Cancer Medicine, Rook's Dermatology Handbook, and Yamada's Textbook of Gastroenterology. The content, which spans medical specialties including cardiology, endocrinology, geriatrics, hematology, internal medicine, neurology, obstetrics, oncology, psychiatry, and rheumatology, will be referenced inside OpenEvidence’s evidence layer, cited with the same transparency that has earned the platform the trust of more than 40% of U.S. physicians.

For clinicians, the practical effect is broader and deeper access to trustworthy evidence at the point of care. The question a physician encounters once in a career is often the one where the evidence is most essential and where a dead-end search carries the highest cost. Wiley's corpus deepens the literature available in OpenEvidence for precisely those queries, expanding the range of clinical questions that return a source-cited, evidence-based answer without leaving the point-of-care workflow.

“At the end of the day, we believe doctors will be able to make better decisions because we’re bringing Wiley’s vast portfolio of peer-reviewed scientific and medical content into OpenEvidence, where those decisions are getting made,” said Matt Kissner, president and CEO of Wiley. “We’re excited about this partnership, which reflects our broader commitment to integrating trusted scientific knowledge into the technologies driving innovation across healthcare and life sciences.”

The partnership positions Wiley and OpenEvidence to explore future collaboration opportunities together, including deepening society relationships, connections across networks, global expansion, and other healthcare and life sciences use cases.

“The gap between published research and clinical practice has persisted for decades. Every content partnership that puts peer-reviewed evidence directly into the physician’s workflow makes that gap narrower. This one makes it meaningfully so,” added Daniel Nadler.

About Wiley
Wiley (NYSE: WLY) is a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning. With more than 200 years at the center of the scholarly ecosystem, Wiley combines trusted publishing heritage with AI-powered platforms to transform how knowledge is discovered, accessed, and applied. From individual researchers and students to Fortune 500 R&D teams, Wiley enables the transformation of scientific breakthroughs into real-world impact. From knowledge to impact: Wiley is redefining what's possible in science and learning. Visit us at Wiley.com and Investors.Wiley.com. Follow us on Facebook, X, LinkedIn and Instagram.

About OpenEvidence
OpenEvidence is the most widely used medical AI platform among U.S. physicians, and is trusted by hundreds of thousands of verified clinicians to make high-stakes clinical decisions at the point of care with answers that are sourced, cited, and grounded in peer-reviewed medical literature. OpenEvidence was founded with the mission to organize and expand the world's collective medical knowledge. Learn more at openevidence.com.

Category: All Corporate News
Category: All Journals and Research